OTC Mevacor CUSTOM Label Illustrates New Approach Toward Approval
This article was originally published in The Tan Sheet
Executive Summary
Proposed labeling used in J&J/Merck's actual use trial for OTC Mevacor (lovastatin 20 mg) directs individuals to obtain follow-up cholesterol testing sooner than did the firm's 2000 proposal for the switch
You may also be interested in...
Mevacor OTC Actual-Use Study Data May Answer Future NDAC Questions
Nearly half of high-risk patients in the Mevacor OTC actual-use study took the low-dose statin only after securing approval from a doctor, writes Eric Brass, MD/PhD, UCLA Medical Center, in a supplement to the Nov. 15 American Journal of Cardiology
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands